ClinicalTrials.gg
WithdrawnNCT03680976ALMAUpdated Sep 21, 2018

Anti-Inflammatory Lipid Mediators in Asthma

A Phase 2 interventional study of CXA-10 and Placebo in Asthma, sponsored by Sally E. Wenzel MD. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-21.

Sponsored by Sally E. Wenzel MD · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
The study will not take place at the University of Pittsburgh

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Enrollment
1,314th of 1,354
0 · median 100
Phase 2
293 of 1,696
23 open now
Registered
1,061st of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 1,314th largest by enrollment of the 1,354 interventional ones that give a count, is one of 293 in phase 2, and was the 1,061st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics. The study's hypothesis is that 150 mg/day of CXA-10 for 12 weeks will alleviate obesity-related airway hyper-reactivity in obese adult asthmatics.

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Obesity
  • Nitrated fatty acids
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adequate completion of process with written documentation. Male and female patients, 18 to 65 yrs old female subjects should be either , surgically sterile, or women of (WOCP) with a negative pregnancy test prior to entering the study and who agree to use an acceptable method of , for the duration of the study.
  2. Diagnosis of asthma: based on previous physician diagnosis for > 6 months, and either baseline pre-bronchodilator (BD) between 50 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response (\<12% change), within 2 years of Visit 0. If no historical reversibility or historical PC20, and the participant does not reverse 12% at V0, the participant can return for V0a to meet this eligibility criteria.
  3. Daily treatment with inhaled and long acting beta agonists (ICS/LABA) combination medication for at least 3 months; on a stable dose for the 4 weeks prior to Visit 0
  4. Asthma control questionnaire ACQ > 1.5 \& ≤ 3
  5. Smoking history \<10 pack years and no smoking in the last year
  6. (BMI) ≥ 30 kg/m2
  7. (HbA1c) \<8%
  8. Average systolic blood pressure \<160 or diastolic \< 100 mmHg (average of three measurements))
  9. Resting HR ≥45 beats per minute (BPM) after 5 minute rest at screening
  10. interval (Fredericia's correction factor) must be ≤430 msec at screening and pre-dose for males and ≤450 msec for females.
  11. For randomization: No exacerbations or treatment failures during the run in. Patients, who exacerbate or experience treatment failure during the run-in, may re-enroll 4 weeks after the exacerbation has resolved (completed course of systemic corticosteroids).

Exclusion criteria

Exclusion Criteria:

  1. Respiratory tract infection within the last 4 weeks
  2. Oral or systemic burst within the last 4 weeks
  3. Asthma-related hospitalization within the last 2 months
  4. Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma
  5. Asthma-related ER visit within the previous 4 weeks
  6. Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, or diabetes at the discretion of the investigator
  7. History of ICU admission/intubation due to asthma in the past year
  8. Current statins use, patients may stop and re-enroll after 4 weeks of stopping statins
  9. Positive pregnancy test at screening and at pre-dose
  10. Women who are breastfeeding
  11. Women of who are unwilling to use an acceptable method of .
  12. Intolerance or to the CXA-10 or it's
  13. Treatment with any drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of dosing (this includes investigational formulations of marketed products, inhaled and topical drugs
  14. Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the Investigator;
  15. Any kind of oral nitrates such as nitroglycerin
  16. Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations within the previous 3 years
  17. Personal or family history of congenital prolonged syndromes or sudden unexpected death due to a cardiac reason
  18. History of any primary , including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin
  19. Cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
  20. History of alcohol or drug abuse in the 6 month period prior to enrollment
  21. Treatment with vitamins, herbal and dietary supplements within 7 days or 5 - ½ lives whichever is longer prior to dosing until the final study visit, whichever is longer prior to dosing until the final study visit. (may rescreen after a )
  22. Resting heart rate ≥100 BPM after 5 minutes rest at screening
  23. Subjects with any other parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study. Any clinically significant abnormalities on 12-lead ECG at screening including, but not limited to any of the following:

    • PR interval >200 msec or \<120 msec
    • Non-specific intra-ventricular conduction delay (IVCD) with QRS duration ≥110 msec and where the morphology does NOT meet criteria for left (LBBB) or right bundle branch block (RBBB)
    • Incomplete RBBB as defined by QRS duration ≥110 msec but \<120 msec with RBBB pattern
    • Complete RBBB and LBBB
    • Evidence of second- or third- degree AV block
    • Pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5 mV)
    • Evidence of ventricular pre-excitation
    • Evidence of left axis deviation (left axis deviation is -30 to -90 degrees) but not normal leftward axis, ST-T wave abnormalities, LBBB and/or RBBB
  24. Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)
  25. (AST) and/or alanine aminotransferase (ALT) >3.0X (ULN), gamma-glutamyl transferase (GGT) >3X ULN, and total >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted. Subjects with indirect total bilirubin up to 3X ULN are presumed to have Gilbert's syndrome and may be enrolled if all other LFTs are WNL
  26. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
  27. Diagnosis of
  28. Patients with multiple sclerosis on dimethyl fumarate (tecfidera)
  29. Patients with asthma on biological therapy (i.e. mepolizumab, omalizumab)
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    10-nitro-octadeca-9-enoic acid (CXA-10)

    CXA-10 150 mg tablet taken orally once a day for 12 weeks

    Drug: CXA-10

  • Placebo comparator
    Placebo

    Placebo 150 mg tablet taken orally once a day for 12 weeks

    Drug: Placebo

Interventions

  • DrugCXA-10

    Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.

    Also known as: 10-nitro-octadeca-9-enoic acid

  • DrugPlacebo

    Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule

06

What researchers measure

Primary outcomes

  1. Change in airway responsiveness after treatment with CXA-10 using a methacholine challenge test

    Measured by the response to administration of methacholine. The PC20 is a calculated value of the amount of methacholine required to cause a 20% fall in the subject's FEV1.

    Time frame: 12 weeks

Secondary outcomes

  1. Treatment with CXA-10 compared to baseline: Change in the concentration of Nitrite/Nitrate (NO2/NO3). and NO2-Conjugated Linoleic Acid (CLA) in plasma and urine

    Measured using analysis of plasma and urine at baseline and after treatment with CXA-10.

    Time frame: 12 weeks

  2. Treatment with CXA-10 compared to baseline: Characterization of the pharmacokinetic (PK) profile of CXA-10 in plasma and urine

    Measured using analysis of plasma and urine at baseline and after treatment with CXA-10.

    Time frame: 12 weeks

  3. Treatment with CXA-10 compared to baseline: Changes in airway epithelial gene expression

    Measured using bronchial samples from the subjects randomized to undergo a bronchoscopy

    Time frame: 12 weeks

07

Study locations

1 site
  • The University of Pittsburgh Asthma Institute at UPMC
    Pittsburgh, Pennsylvania 15213, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03680976
Lead sponsor
Sally E. Wenzel MD
Responsible party
Sally E. Wenzel MD (Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Sep 21, 2018
Primary completion
Apr 2021 (estimated)
Completion
Apr 2021 (estimated)
Last update
Sep 21, 2018

Study contacts

Sally E Wenzel, MD
principal investigator · The University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CXA-10

Start the discussion